No CrossRef data available.
Article contents
The first series of implantations of the Harmony valve in Europe: the beginning of a new era for percutaneous pulmonary valve implantation also in the Old Continent?
Published online by Cambridge University Press: 14 February 2025
Abstract
For many patients with right ventricular outflow tract (RVOT) dysfunction, percutaneous pulmonary valve implantation (PPVI) offers a less-invasive alternative treatment option to surgery with a similar long-term result. However, the implantation of the valves recently available on the European market was only possible in patients with a limited maximal RVOT diameter. In patients with large RVOT, surgical treatment has remained the only possible treatment modality until recently. The self-expandable Harmony transcatheter pulmonary valve is a valve dedicated for patients with severe pulmonary regurgitation in the native and surgically repaired wide RVOT. The initial experience worldwide with this valve is very promising. However, it has not been implanted in Europe until recently. We report on four young adult patients with severe pulmonary valve regurgitation who underwent a successful PPVI with Harmony valve implantation. There were no serious complications in our small study group. In conclusion, the Harmony valve may offer a less-invasive and safe treatment alternative to surgery for patients in whom the available balloon-expandable valves offer only limited applicability. This valve has only recently become accessible on the European market.
- Type
- Brief Report
- Information
- Copyright
- © The Author(s), 2025. Published by Cambridge University Press
References
Bonhoeffer, P, Boudjemline, Y, Saliba, Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 2000; 356 (
9239
): 1403–1405. DOI: 10.1016/S0140-6736(00)02844-0.CrossRefGoogle Scholar
Stefanescu Schmidt, AC, Armstrong, AK, Aboulhosn, JA, et al. Transcatheter pulmonary valve replacement with balloon-expandable valves: utilization and procedural outcomes from the IMPACT registry. JACC Cardiovasc Interv 2024; 17 (
2
): 231–244. DOI: 10.1016/j.jcin.2023.10.065.CrossRefGoogle ScholarPubMed
Georgiev, S, Ewert, P, Eicken, A, et al. Munich comparative study: prospective long-term outcome of the transcatheter melody valve versus surgical pulmonary bioprosthesis with up to 12 Years of follow-up. Circ Cardiovasc Interv 2020; 13 (
7
): e008963. DOI: 10.1161/CIRCINTERVENTIONS.119.008963.CrossRefGoogle ScholarPubMed
Gillespie, MJ, McElhinney, DB, Jones, TK, et al. 1-year outcomes in a pooled cohort of harmony transcatheter pulmonary valve clinical trial participants. JACC Cardiovasc Interv 2023; 16 (
15
): 1917–1928. DOI: 10.1016/j.jcin.2023.03.002 Epub 2023 May 17.CrossRefGoogle Scholar
Taylor, A, Yang, J, Dubin, A, et al. Ventricular arrhythmias following transcatheter pulmonary valve replacement with the harmony TPV25 device. Catheter Cardiovasc Interv 2022; 100 (
5
): 766–773. DOI: 10.1002/ccd.30393 Epub 2022 Oct 5.CrossRefGoogle ScholarPubMed
Benson, LN, Gillespie, MJ, Bergersen, L, et al. Three-year outcomes from the harmony native outflow tract early feasibility study. Circ Cardiovasc Interv 2020; 13 (
1
): e008320. DOI: 10.1161/CIRCINTERVENTIONS.119.008320 Epub 2020 Jan 9.CrossRefGoogle ScholarPubMed
Goldstein, BH, McElhinney, DB, Gillespie, MJ, et al. Early outcomes from a multicenter transcatheter self-expanding pulmonary valve replacement registry. J Am Coll Cardiol, Apr 2024; 83 (
14
): 1310–1321. DOI: 10.1016/j.jacc.2024.02.010.CrossRefGoogle ScholarPubMed
Gatzoulis, MA, Balaji, S, Webber, SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of fallot: a multicentre study. Lancet 2000; 356 (
9234
): 975–981. DOI: 10.1016/S0140-6736(00)02714-8.CrossRefGoogle ScholarPubMed
Jin, Q, Long, Y, Zhang, G, et al. Five-year follow-up after percutaneous pulmonary valve implantation using the Venus P-valve system for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract. Catheter Cardiovasc Interv 2024; 103 (
2
): 359–366. DOI: 10.1002/ccd.30916 Epub 2023 Dec 6.CrossRefGoogle Scholar
Odemis, E, Yenidogan, I, Kizilkaya, MH. Early results of Pulsta® transcatheter heart valve in patients with enlarged right ventricular outflow tract and severe pulmonary regurgitation due to transannular patch. Cardiol Young 2023; 33 (
10
): 1935–1935. DOI: 10.1017/S1047951122003870 Epub 2022 Nov 16. Erratum in: Cardiol Young. 2023-10.CrossRefGoogle ScholarPubMed
Dimas, VV, Babaliaros, V, Kim, D et al. Multicenter pivotal study of the alterra adaptive prestent for the treatment of pulmonary regurgitation. JACC Cardiovasc Interv 2024; 17 (
19
): 2287–2297. DOI: 10.1016/j.jcin.2024.07.036.CrossRefGoogle ScholarPubMed